Last reviewed · How we verify
dorzolamide/timolol maleate fixed combination
Dorzolamide inhibits carbonic anhydrase to reduce aqueous humor production, while timolol blocks beta-adrenergic receptors to further decrease intraocular pressure.
Dorzolamide inhibits carbonic anhydrase to reduce aqueous humor production, while timolol blocks beta-adrenergic receptors to further decrease intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | dorzolamide/timolol maleate fixed combination |
|---|---|
| Sponsor | Pharmaceutical Research Network |
| Drug class | Carbonic anhydrase inhibitor / Beta-adrenergic antagonist combination |
| Target | Carbonic anhydrase II; Beta-adrenergic receptors (β1 and β2) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Dorzolamide is a topical carbonic anhydrase inhibitor that decreases aqueous humor secretion in the eye by inhibiting the enzyme carbonic anhydrase II. Timolol maleate is a non-selective beta-adrenergic antagonist that reduces aqueous humor production and may increase uveoscleral outflow. The fixed combination provides complementary mechanisms to lower intraocular pressure more effectively than either agent alone.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Ocular burning or stinging
- Blurred vision
- Bitter taste
- Ocular allergic reactions
- Headache
- Systemic beta-blocker effects (bradycardia, fatigue)
Key clinical trials
- Dorzolamide+Timolol Multidose Preservative-free vs Dorzolamida+Timolol BAK Preserved Efficacy and Safety (PHASE4)
- Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients (PHASE4)
- From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy (NA)
- A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma (PHASE4)
- 24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations (PHASE4)
- 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy (PHASE4)
- Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide (PHASE2)
- Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |